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Obesity Management: Clinical
Review and Update of the
Pharmacologic Treatment Options
Raymond A. Plodkowski, MD; Megan E. McGarvey, MD; Keith Reisinger-Kindle; Bradley Kramer;
Erik Nelson, DO; Jennifer Lee, DO; and Quang T. Nguyen, DO

The toolbox of medications available for medical weight management is more robust than ever
and includes a wide variety of mechanisms of actions and options for patients.

O

ver the past decade the prevalence of obesity as defined
by a body mass index (BMI)
≥ 30 kg/m2 has significantly
increased. In the U.S. more than
78 million adults are estimated to be
obese.1 The World Health Organization projects that by 2025 up to half
the U.S. population will be obese.
Cardiovascular disease (CVD) and
diabetes mellitus (DM) are the main
comorbid conditions that are complicated by obesity. Initial weight loss
of 5% to 10% of total body weight
reduces CVD risk factors, prevents or
delays the development of type 2 DM
(T2DM) and improves the health
consequences of obesity.2
To date, public health initiatives
that have focused on obesity prevention and lifestyle intervention have
had marginal success. In recent years,
anti-obesity drug therapies have had
a limited role in clinical treatment
algorithms. In 2013, the American

Medical Association acknowledged
obesity as a disease. In turn, this
acknowledgement allowed the recognition of anti-obesity drugs as acceptable therapeutic adjuncts to
intensive lifestyle intervention that
could address the growing obesity
endemic.
In the past, medications for
weight reduction were limited. Several that were FDA approved had to
be removed from the market due to
safety concerns. With few approved
options, clinicians often had to resort to off-label use of medications.
However, the landscape has changed
with 4 new medications gaining recent FDA approval. This review covers older available medications and
the newer medications that are now
available.

SYMPATHOMIMETICS
Sympathomimetic drugs have been
approved for use as a pharmaco-
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logical method to lose weight since
1960. Of the many versions of this
drug class that have been available
since then, there are 4 major versions
available today. These include diethylpropion3 and benzphetamine,4 both
approved in 1960; phendimetrazine,
approved in 1976;5 phentermine, approved in 1980;6 and phentermine
hydrochloride, approved in 2012.7
Despite the existence of several other
classes of drugs to treat obesity, phentermine remains the most often prescribed weight loss drug in the U.S.8
Although the mechanism of action
(MOA) of sympathomimetic drugs
is not particularly clear, weight loss
from these medications is believed
to be due to the increase in the release of biogenic amines (mainly
norepinephrine, but also possibly
dopamine), from storage sites in
nerve terminals. It is possible that
these drugs slow catecholamine metabolism by inhibiting the actions of
monoamine oxidase. The resulting
increase in amine availability, particularly in the lateral hypothalamic feeding center, is associated with reduced
food intake. Interestingly, injection
of these drugs into the ventromedial
satiety center dooes not seem to suppress food intake, and the effects of
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biogenic amines on increasing metabolism does not seem to play a significant role in weight loss in patients
on these medications.9
Each of these drugs is rapidly absorbed from the gastrointestinal (GI)
tract except for phentermine hydrochloride, the newest of the medications in this class. Phentermine
hydrochloride is a sublingual tablet
that is readily absorbed through the
buccal mucosa.5 All of the drugs in
this class are excreted through the
kidneys, with varying rates. Each
drug’s excretion is highly dependent on the pH of the urine—more
alkaline conditions result in less excretion and more acidic conditions
result in more excretion. As a result,
these drugs should be used with caution in patients with renal impairment; however, there are no specific
contraindications listed for patients
with poor renal function.
The adverse effects (AEs) for this
drug class are to be expected from
an increase in the release of biogenic amines in the central nervous
system (CNS). The most common
AEs include palpitations, tremors,
restlessness, insomnia, dry mouth,
constipation, diaphoresis, changes in
libido, and irritability. The more dangerous AEs that have been observed
include arrhythmias, hypertension,
dependency/abuse, convulsions,
acute transient ischemic colitis, and
acute urinary retention secondary to increased bladder sphincter
tone, transient hyperthyroxemia, and
paranoia.10
Several contraindications exist for
sympathomimetics, including the
presence of advanced arteriosclerosis, symptomatic CVD, moderate to
severe hypertension, hyperthyroidism, glaucoma, patients in an agitated state, or those with a history of
amphetamine abuse. The warnings
for prescribers include pulmonary
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hypertension and cardiomyopathy
secondary to chronic use of sympathomimetics, and valvular heat
disease secondary to use of sympathomimetics with additional anorectic agents.
Additional precautions should be
considered in those with a history of
anxiety/psychosis, those who operate
machinery and motor vehicles, and
even those with mild hypertension.
The data surrounding the effects of
sympathomimetics on blood pressure (BP) appears to be conflicting
and the relationship does not seem
to have been significantly studied in
depth to warrant any definitive conclusions. The MOA of this drug class
itself is enough to urge caution to
prescribers.11 Special attention should
be given to patients with diabetes
when using sympathomimetics. A
reduction of insulin dose or oral hypoglycemic dose may be necessary in
some people with diabetes.
Only diethylpropion is pregnancy
category B, whereas the others drugs
in this class are pregnancy category
X. It has been demonstrated that diethylpropion and benzphetamine are
secreted into breastmilk; insufficient
data exist to suggest whether or not
phentermine and phendimetrazine
are present in breastmilk. All drugs in
this class should be used in caution
with breastfeeding mothers.
Although all 4 drugs are registered as controlled substances, benzphetamine and phendimetrazine are
schedule III and phentermine and diethylpropion are schedule IV, despite
evidence suggesting the potential for
abuse to be extremely low.12,13 Phentermine has been approved for adults
aged > 18 years, phendimetrazine
has been approved for those aged
> 17 years, diethylpropion has been
approved for those aged > 16 years,
and benzphetamine has been approved for those aged > 12 years.

There is a wealth of literature
surrounding the effectiveness of
this drug class for weight loss. One
of the longest trials of phentermine
was recently conducted as part of the
initial component of a FDA study
for the newly approved topiramatephentermine combination. Weight
loss at 6 months in the phentermineonly group was significantly higher
at -5.8% compared with -1.5% with
the placebo group in the last observation carried forward-Intent to treat
(LOCF-ITT) analysis.14 Similarly, a
long-term study looking at diethylpropion examined the use of diethylpropion for up to a year vs placebo.
Participants administered diethylpropion lost a mean 9.8% of original
weight vs 3.7% in the placebo group
in the first 6 months alone.15
Several meta-analyses and review
papers have been authored that examine and analyze the published data
on this drug class overall and comparatively within this class. Haddock
and colleagues in 2002 reviewed the
numerous clinical trials associated
with each drug in this class, in addition to several other classes, and
found that although each drug demonstrated a significant advantage vs
placebo in weight loss, there was not
a specific drug that was significantly
superior to any of the others.16
These results seem to be in relative agreement with additional studies like that published by Suplicy
and colleagues, which demonstrated
that several sympathomimetics
were better than placebo in weight
loss, and that there was little difference between the specific drugs in
the class.17 However, it should be
noted that as highlighted in a review
by Ioannides-Demos and colleagues
in 2005, the vast majority of studies that had been performed on this
drug class focused on short-term use
(< 16 weeks) and none of the
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Table 1. Clinical Trial Results on Pharmacologic Obesity Treatment Options
Generic Name

Bupropion/
Naltrexone

Liraglutide

Lorcaserin

Orlistat

Phentermine/
Topiramate

Maintenance Dose

16 mg/180 mg bid

3 mg qd

10 mg bid

120 mg tid

7.5 mg/46 mg qd

Medication

Control

44.4

43.7

45.2

45.0

43.8

43.7

43.2

Gender (% female)

85

85

78.7

78.1

80.5

78.0

Baseline weight, kg

99.7

99.5

106.2

106.2

100.1

Baseline waist
circumference, cm

108.8

110.0

115.0

114.5

Baseline BMI

36.1

36.2

38.3

Completers weight
loss, %

-8.0

-1.9

LOCF weight
loss, %

-6.1

≥ 5% LOCF weight
loss, %
≥ 10% LOCF
weight loss, %

Age, y

Medication Control Medication

Control Medication Control

Medication

Control

41.6

51.1

51.2

79

78

70.0

70.0

100.5

100.5

101.8

102.6

103.3

108.9

110.2

n/a

n/a

112.6

113.4

38.3

36.0

35.9

36.0

36.1

36.2

36.7

-9.2

-3.5

-7.9

-4.0

-8.78

-4.26

-9.6

-1.6

-1.4

-8.0

-2.6

-5.8

-2.8

-7.94

-4.14

-8.1

-1.4

48

16

63.2

27.1

47.2

25.0

50.5

30.7

62

21

25

7

33.1

10.6

22.6

9.7

28.6

11.3

37

7

Abbreviations: BMI, body mass index; LOCF, last observation carried forward.

sympathomimetics listed here have
been approved for long-term use.18

ORLISTAT

Orlistat 120 mg was approved in
1999 as a reversible inhibitor of GI
lipases that specifically reduced the
absorption of dietary fat due to the
inhibition of triglyceride hydrolysis.19
Orlistat was later approved in 2007
for release in a reduced dosage form
(60 mg) for over-the-counter sales.20
Orlistat forms a covalent bond
with the active serine residue site of
gastric and pancreatic lipases in the
lumen of the stomach and small intestine. The inhibition of these enzymes causes dietary fat to remain
undigested as triglycerides, which
cannot be converted to absorbable
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free fatty acids and monoglycerides,
leading to decreased calorie absorption. Orlistat is not systemically absorbed and is eliminated mainly
through feces. Some metabolism occurs in the GI wall.21
Orlistat is most known for its
GI AEs. Because it is most active in
the lumen of the GI system and reduces the absorption of triglycerides,
many AEs are related to malabsorption. The most common issues 1 year
after starting the drug were oily
spotting (26.6% vs 1.3% placebo);
flatus with discharge (23.9% vs
1.4% placebo); fecal urgency (22.1%
vs 6.7% placebo); fatty/oily stool
(20% vs 2.9% placebo); increased
defecation (10.8% vs 4.1% placebo);
and fecal incontinence (7.7% vs

JANUARY 2016

0.9% placebo) (Table 1). Most of
these AEs were greatly reduced after
taking the drug for 2 years. Orlistat
also has more serious AEs noted, including abdominal pain/discomfort;
nausea; infectious diarrhea; rectal
pain/discomfort; tooth disorder;
gingival disorder; vomiting; upper
respiratory infection; lower respiratory infection; ear, nose and throat
symptoms; back pain; arthritis; myalgia; joint disorders; tendonitis;
headache; dizziness; fatigue; sleep
disorders; rash; dry skin; menstrual
irregularity; vaginitis; urinary tract
infection; and psychiatric disorders,
although these did not differ markedly from placebo.
One of the most serious AEs reported was fulminate hepatic failure,

www.fedprac.com
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though this AE is rare. Thirteen cases
of liver injury were reported with the
120-mg prescription dose of orlistat
and 1 case report in the U.S. involved
the 60-mg over-the-counter dosage
of orlistat.21,22 The FDA suggests that
patients talk to their physicians about
risks of liver failure, and that physicians should educate their patients
about signs and symptoms of liver
failure so that patients can stop taking orlistat and seek immediate medical help if symptoms occur.
One of the first published trials
was the European Multicentre Orlistat Study Group, which included
743 participants with BMI between
28 kg/m2 and 47 kg/m2 from 15 different European centers. To test
adherence, a 4-week single blind
placebo lead-in was started with a
hypocaloric diet. The first stage was
completed by 688 patients who then
proceeded to the double blind randomized control trial portion with
a hypocaloric diet. From the start of
lead-in to the end of year 1, the orlistat group weight decreased 10.2%
(10.3 kg) vs 6.1% (6.1 kg) in the placebo group. The placebo subtracted
difference between the groups was
3.9 kg (P < .001).23
A U.S.-based randomized doubleblind placebo-controlled multicenter
study included 796 obese patients
with BMI between 30 kg/m 2 and
44 kg/m2. Patients were assigned to 1
of 3 groups: placebo, orlistat 60 mg 3
times daily, or orlistat 120 mg 3 times
daily. All groups were given a reduced energy diet. Patients in the orlistat 120 mg group lost significantly
more weight than did the placebo
group, -8.78% vs -4.26% respectively
in year 1 in the completer analysis
(P = .001). More participants who
were treated with orlistat 120 mg lost
5% or more of their initial weight in
year 1 compared with placebo, 50.5%
vs 30.7% respectively (P < .001).24

www.fedprac.com

In the XENDOS study the primary outcome measurement was
time to onset of T2DM. Eligible participants were aged 30 to 60 years,
with a BMI > 30 kg/m2. All patients
had a 75-g oral glucose tolerance test
and were required to have normal
glucose tolerance or impaired glucose
tolerance, but not T2DM. The double-blind randomized controlled trial
included 3,305 subjects and compared a group taking 120 mg orlistat
3 times daily vs placebo. All patients
were prescribed a reduced-calorie
diet (800 kcal/d deficit) containing
30% of calories from fat. Patients
were also encouraged to walk at least
1 kilometer daily in addition to their
usual physical activity. Incidence
of T2DM after 4 years was 6.2% in
the orlistat group and 9.0% in the
placebo group, reflecting a 37.3%
risk reduction in the orlistat group
(P = .0032).25,26

LORCASERIN
In 2012, lorcaserin HCl was FDA approved as a schedule IV drug for use
as a weight loss medication as an adjunct to a reduced-calorie diet and
increased physical activity. Lorcaserin
is thought to act on 5-hydroxytryptamine-2c (5HT2c) receptors on the
pro-opiomelanocortin (POMC) neurons in the arcuate nucleus, causing
release of alpha-melanocortin-stimulating hormone (alpha-MSH), which
in turn acts on melanocortin-4 receptors in the paraventricular nucleus to
suppress appetite. At the maximum
suggested dose of 10 mg twice daily,
lorcaserin binds with 15 to 100 times
greater affinity to 5HT2c receptors
compared with 5HT2a and 5HT2b
receptors respectively.
Indications for lorcaserin include
patients with BMI ≥ 30 kg/m 2 or
≥ 27 kg/m2 or greater with a weightrelated comorbid condition such as
hypertension, dyslipidemia, cardio-

vascular disease, impaired glucose
tolerance, or sleep apnea.
The efficacy of lorcaserin for
weight loss has been evaluated in
3 separate trials. The trials were randomized, double blinded and placebo controlled. The BLOOM trial,
which included 3,182 patients with
a mean BMI of 36.2 kg/m2, evaluated
the efficacy of lorcaserin as a weight
loss adjunct. 27 Patients with preexisting valvular disease, uncontrolled hypertension, or a major
psychiatric condition were excluded. After initial randomization,
patients were assigned to receive
either lorcaserin 10 mg twice daily
or a placebo. The primary endpoint
was a 5% weight reduction from
baseline by the end of 2 years. At
1 year, 47.5% of patients in the lorcaserin group and 20.3% in the placebo group had lost ≥ 5% of their
body weight (P <.001). The average loss for the lorcaserin group was
5.8 ± 0.2 kg and 2.2 ± 0.1 kg for the
placebo group at 1 year (P < .001).
The BLOSSOM trial was a 1-year
study of 4,008 patients aged 18 to
65 years. The trial evaluated the effects of lorcaserin on body weight,
CVD risk factors, and safety in obese
and overweight patients.28 Patients
were randomized in a 2:1:2 ratio to
receive lorcaserin 10 mg twice daily,
lorcaserin 10 mg once daily, or placebo. The primary endpoint was the
proportion of patients achieving at
least 5% reduction in body weight.
Completer analysis showed weight
reduction in the placebo group was
4.0% and 7.9% in the lorcaserin group
(P < .001). In the modified intent-totreat/last observation carried forward
analysis (MITT/LOCF), a statistically
significant 47.2% of patients receiving lorcaserin 10 mg twice daily and
40.2% of patients receiving lorcaserin
10 mg once daily lost at least 5% of
baseline body weight; compared with
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Table 2. Recent FDA-Approved Pharmacologic Obesity Treatments
Maintenance
Dose

Weight Loss vs
Placebo, %

Significant
Adverse Event vs
Placebo

Discontinuation
Rate vs
Placebo, %

Renal or Hepatic
Dose Adjustment

Drug (Brand)

Mode of Action

Naltrexone/
Bupropion
(Contrave)

Opioid receptor
antagonist/
Aminoketone
antidepressant

16 mg/180 mg
BID

8.1 vs. 1.6

Nausea:
28.9% vs 5.3%
Constipation:
19.1% vs. 7.1%
Headache:
17.5% vs. 8.7%

24% vs. 13.8%

No dose adjustment

Liraglutide
(Saxenda)

GLP-1 receptor
agonist

3 mg

9.2 vs. 3.0

Nausea:
39.3% vs. 13.8%
Diarrhea:
20.9% vs. 9.9%
Constipation:
19.4% vs. 8.5%

9.9% vs. 3.8%

Use with caution in
moderate to severe
renal impairment or
hepatic impairment

Locarserin
(Belviq)

Serotonin 2C
receptor agonist

10 mg BID

5.8 vs 2.8

Nausea:
9.4% vs. 7.9%
Back pain:
11.7% vs. 7.9%
Headache:
14.5% vs. 7.1%

22.1% vs. 37.9%

Use with caution in
moderate to severe
renal impairment or
hepatic impairment

Orlistat
(Xenical)

Gastrointestinal
lipase Inhibitor

120 mg TID

7.9 vs 4.2

Oily spotting:
26.6% vs. 1.3%
Flatus with
discharge:
23.9% vs 1.4%
Fecal urgency:
22.1% vs. 6.7%

8% vs. 4%

No dose adjustment

Phentermine/
Topiramate
(Qsymia)

Sympathomimetic/
Unknown

7.5 mg/46 mg

8.0 vs 1.6

Constipation:
16.3% vs. 7.1%
Paresthesia:
13.7% vs. 2.6%
Dry mouth:
13.7% vs. 2.2%

11.6% vs 8.4%

Use with caution in
moderate to severe
renal impairment or
hepatic impairment

25% of patients receiving placebo
(P < .001). Weight loss of at least 10%
was achieved by 22.6% of patients receiving lorcaserin 10 mg twice daily,
and 17.4% of patients receiving 10 mg
daily compared with 9.7% of patients
in the placebo group (P < .001).
The most common AEs noted
were headache, nausea, and dizziness. Echocardiographic evidence of
valvulopathy occurred in 2% of patients taking lorcaserin 10 mg twice
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daily and those taking the placebo.
Lorcaserin administered in conjunction with a diet and exercise program
was associated with an overall reduction in baseline BMI when compared
with placebo over the year.
The BLOOM-DM study evaluated efficacy and safety of lorcaserin
for weight loss in 604 patients with
T2DM over the course of 1 year.29
Patients had a hemoglobin A1c (A1c)
of 7% to 10% and were treated with

JANUARY 2016

metformin, a sulfonylurea, or both.
The primary endpoint was a 5%
weight reduction from baseline at the
end of 1 year. Patients were randomized into 3 groups: 1 group received
lorcaserin 10 mg twice daily, 1 group
took lorcaserin 10 mg daily, and
1 group received the placebo. A statistically significant 37.5% of patients
taking lorcaserin 10 mg twice daily
achieved > 5% body weight reduction,
compared with 44.7% in the lorcase-
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rin 10 mg daily group, and 16.1% in
the placebo group. Overall reductions
in A1c and fasting glucose were observed in both lorcaserin groups taking as compared with placebo. Patient
A1c decreased 0.9 ± 0.06 with lorcaserin 10 mg bid, 1.0 ± 0.09 with lorcaserin 10 mg qd, and 0.4 ± 0.06 with the
placebo (P < .001). Fasting glucose in
the lorcaserin bid, lorcaserin qd, and
placebo groups decreased 27.4 ± 2.5
mg/dL, 28.4 ± 3.8 mg/dL, and 11.9
± 2.5 mg/dL, respectively (P < .001).
Symptomatic hypoglycemia occurred
in 7.4% of patients on lorcaserin bid,
10.5% on lorcaserin qd, and 6.3% on
placebo. Headache, back pain, nasopharyngitis, and nausea were among
the most commonly reported AEs.
As lorcaserin is a serotonergic agonist, potential interactions exist when
used with other medications affecting
serotonin. Most notably, serotonin
syndrome and neuroleptic malignant
syndrome-like reactions may occur.
Because of this, it is recommended
to avoid selective serotonin re-uptake
inhibitors (SSRIs), selective norepinephrine reuptake inhibitors, tricyclic antidepressants, bupropion,
triptans, monoamine oxidase inhibitors, lithium, dextromethorphan,
and dopamine agonists. Lorcaserin
seems to be safe in those patient populations with mild hepatic as well as
mild renal impairment; however, it
is not recommended for those with
severe renal impairment. Given the
multiple enzymatic pathways used to
metabolize lorcaserin, there is a low
probability for cytochrome drug interactions. Safety has not been well
evaluated in patients aged < 18 years
and those that are pregnant (pregnancy category X).
Adverse events include headache,
dizziness, fatigue, nausea, and dry
mouth. Other notable AEs include
nasopharyngitis and URI. Hypoglycemia appeared to be more common in
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patients with DM taking lorcaserin.
Cognitive impairment and psychiatric disorders including euphoria and
hallucinations were also reported.
Notably, valvular heart disease has
been reported in patients who take
medications with 5HT2b activity. In
a 1-year clinical trial, a small number of patients were found to develop
valvular regurgitation. Furthermore,
bradycardia, priapism, leucopenia, elevated prolactin, and pulmonary hypertension have also been observed.
Caution is recommended if symptoms of any of the aforementioned
conditions are noticed.

QSYMIA
The schedule IV controlled substance
Qsymia (Vivus, Mountain View, CA)
is a combination of phentermine, an
anorexigenic agent, and topiramate
extended-release, an antiepileptic
drug. In July of 2012 it was approved
for chronic weight management as
an addition to a reduced-calorie diet
and exercise. The drug is approved
for adults with a BMI ≥ 30 kg/m2 or
adults with a BMI ≥ 27 kg/m2 who
have at least 1 weight-related condition such as hypertension, T2DM, or
dyslipidemia.30
In 1996 topiramate was approved
by the FDA for the treatment of
seizure disorders and was also approved for migraine prophylaxis in
2004. In patients who were treated
with topiramate for seizure disorders and migraines, weight loss and
a reduction in visceral body fat has
been observed.31 The precise MOA of
topiramate in regards to weight loss
is not fully understood. It may be due
to its effects on both appetite suppression and satiety enhancement.
Topiramate exhibits a combination
of properties including modulatory
effects on sodium channels, enhancement of GABA-activated chloride
channels, inhibition of excitatory

neurotransmission through actions
on kainite and AMPA receptors, and
inhibition of carbonic anhydrase
(CA) isoenzymes in particular CA II
and IV.14
The combination of phentermine
and topiramate is a once-daily formulation that is designed to provide
an immediate release of phentermine
and a delayed release of topiramate,
allowing a peak exposure of the
phentermine in the morning and a
peak concentration of topiramate in
the evening. It should be taken in the
morning in order to avoid the possibility of insomnia that can occur if
taken in the evening. It can be taken
with or without food. The recommended dose is as follows: Start treatment with Qsymia 3.75 mg/23 mg
extended-release daily for 14 days;
after 14 days increase to the recommended dose of Qsymia 7.5 mg/
46 mg once daily.
Weight loss should be evaluated
after 12 weeks at the higher dose. If
at least 3% of baseline body weight
has not been lost at that time, discontinue or escalate the dose. To escalate the dose: Increase to Qsymia
11.25 mg/69 mg daily for 14 days;
followed by Qsymia 15 mg/92 mg
daily. Evaluate weight loss following
dose escalation to Qsymia 15 mg/
92 mg after an additional 12 weeks
of treatment. If at least 5% of baseline body weight has not been lost
on Qsymia 15 mg/92 mg, discontinue as directed. It is important not
to suddenly discontinue, as this may
cause seizures. Patients should be
slowly titrated off the medication.
In vitro studies of phentermine and topiramate indicate that
these drugs are not likely to cause
clinically significant interactions
with drugs using the cytochrome
P450 enzyme pathways, or those
involved in plasma protein binding
displacement; however there is evi-
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dence suggesting that ethinyl estradiol levels may be decreased by 16%,
thus raising a concern about the possibility of decreased contraceptive
efficacy.31 In patients with moderate
(creatine clearance ≥ 30 mL/min to
< 50 mL/min) and severe renal dysfunction (< 30 mL/min), the maximum dose of should not exceed
7.5 mg/46 mg.
Qsymia was evaluated in 3 phase
3 trials for its long-term efficacy
and safety. In all trials, diet and lifestyle counseling were provided for
all patients. The first of these studies was OB-301, a 28-week confirmatory trial with a factorial design
involving 7 treatment arms, tested
2 fixed-dose Qsymia combinations—
regular dose (7.5 mg/46 mg) and
maximum dose (15 mg/92 mg)—as
well as regular and maximum doses
of the individual constituent drugs
vs placebo.32 The study randomized
756 obese patients with a BMI range
of 30 kg/m2 to 45 kg/m2 to 1 of the
7 treatment arms for 28 weeks. Patients treated with maximum-dose
Qsymia achieved an average weight
change of -9.0%, vs -1.5% with placebo (P < .0001). Weight change
with regular-dose Qsymia was -8.2%.
Weight changes with monotherapies
were: -6.1% with topiramate 92 mg,
-4.9% with topiramate 46 mg, -5.8%
with phentermine 15 mg, and -5.2%
with phentermine 7.5 mg.
OB-302 was a 56-week trial that
randomized 1,267 morbidly obese
patients with a BMI ≥ 35 kg/m2 without significant comorbidities to
low-dose Qsymia (3.7 mg/23 mg),
maximum-dose Qsymia (15 mg/
92 mg), or placebo.33 At baseline, the
mean BMI for the entire study cohort
was 42 kg/m2. Mean weight changes
were -1.6% with placebo, -5.1% with
low-dose Qsymia, and -10.9% with
maximum-dose Qsymia. The proportions of patients achieving ≥ 5%
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weight loss were: 17% with placebo,
45% with low-dose Qsymia, and 67%
with maximum-dose Qsymia.
CONQUER was the largest of the
phase 3 trials. It randomized 2,487
overweight or obese patients with
a BMI of 27 kg/m2 to 45 kg/m2 and
≥ 2 obesity-related comorbidities
(hypertension, dyslipidemia, T2DM,
prediabetes or abdominal obesity)
to receive a placebo, regular-dose
Qsymia, or maximum-dose Qsymia
for 56 weeks.34 In the completer population, mean weight changes in the
placebo, regular dose Qsymia, and
maximum-dose Qsymia groups were
-1.6%, -9.6% (P <.0001), and -12.4%
(P < .0001); and weight loss of ≥ 5%
was achieved by 21%, 62%, and 70%,
respectively. Relative to placebo, there
were greater reductions in systolic BP,
triglycerides, and fasting insulin with
both doses of Qsymia.
Patients should not take Qsymia
if they are pregnant, planning to
become pregnant, or become pregnant during Qsymia treatment as
there is an increased risk of birth
defects, namely cleft lip and cleft
palate. Women who can become
pregnant should have a negative pregnancy test before taking
Qsymia and every month while on
the medication. They should use
effective birth control consistently
while taking Qsymia.
Qsymia is contraindicated in patients with glaucoma and patients
who have hyperthyroidism. Qsymia
can cause an increase in resting heart
rate and regular monitoring of resting heart rate is recommended, especially in patients with cardiac or
cerebrovascular disease. It has not
been studied in patients with recent
or unstable cardiac or cerebrovascular disease and therefore use is not
recommended.
Qsymia can cause mood disorders such as anxiety and depression
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and can increase the risk of suicidal
thoughts. Patients should be monitored for worsening depression, suicidal thoughts or behavior, or any
unusual changes in mood or behavior. It is not recommended in patients
with a history of suicidal attempts
or active suicidal ideation. Qsymia
can cause cognitive dysfunction. It
can cause confusion, problems with
concentration, attention, memory, or
speech. Patients should be cautioned
about operating automobiles and
hazardous machinery.
Normal anion gap hyperchloremic metabolic acidosis has been
reported in patients treated with
Qsymia. If this does develop and
persists, consideration should be
given to either reduce the dose or
discontinue Qsymia.
Weight loss may increase the risk
of hypoglycemia in patients with
T2DM treated with insulin and/or
insulin secretagogues (eg, sulfonylureas). Qsymia has not been studied in combination with insulin. A
reduction in the dose of antidiabetic
medications, which are nonglucose
dependent, should be considered to
reduce the risk of hypoglycemia.
The most common AEs in controlled clinical studies (≥ 5% and at
least 1.5 times placebo) included paraesthesia in the hands, arms, feet or
face, dizziness, dysgeusia, insomnia,
constipation, and dry mouth.

CONTRAVE
In 2014, the FDA approved Contrave
(Takeda, Deerfield, IL) as treatment
option for chronic weight management in addition to reduced-calorie
diet and physical activity. The combination of naltrexone hydrochloride
and bupropion hydrochloride was
originally introduced for the treatment of opioid addiction and later
expanded to include the treatment of
alcoholism. The antidepressant bu-
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propion was approved in the U.S. in
1989. It is structurally different from
all other marketed antidepressants
(ie, tricyclics, tetracyclics, and SSRIs),
but closely resembles the structure of
diethylpropion, an appetite depressant with minimal CNS effects.35
This drug is approved for adults
with BMI ≥ 30 kg/m2 and for adults
with BMI > 27 kg/m2 with at least
1 weight-related risk factors such
as hypertension, T2DM, or dyslipidemia. It should be used as an adjunct to diet and exercise and is not
approved for use for depression even
though it contains bupropion.
Naltrexone is a pure opioid antagonist with high affinity to μ-opioid
receptor, which is implicated in eating
behavior. Naltrexone is rapidly and
nearly completely absorbed from the
GI tract after oral administration. The
time to peak plasma concentration is
about 1 hour. Naltrexone is well absorbed but first pass extraction and
metabolism by the liver decreases oral
bioavailability to between 5% to 40%.
Primary elimination of naltrexone
and its metabolites is renal excretion.
Bupropion is a weak inhibitor of
neuronal reuptake of dopamine and
norepinephrine. This drug is used
to treat depression and seasonal affective disorder, and aid in smoking
cessation. Bupropion is absorbed
rapidly after oral administration, but
the absolute oral bioavailability of
bupropion is not known because an
IV preparation is not available. The
time to peak plasma concentrations
of bupropion is within 2 hours of
oral administration. Bupropion is extensively metabolized by the liver to
multiple metabolites. Primary elimination of bupropion is urinary excretion. However, hepatic and renal
impairment may affect the elimination of bupropion and its metabolites.
Patients with hepatic or renal impairment should use a reduced dosage.
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Combination therapy has been
found to have complementary actions on CNS to reduce food intake.
They are believed to dampen CNS reward pathways, taking away the compulsive feeding behavior and pleasure
of feeding, ultimately leading to
weight loss. Bupropion stimulates
hypothalamic pro-opiomelanocortin
neurons (POMC), which results in
reduced food intake and increased
energy expenditure. Naltrexone
blocks opioid-receptor mediated
POMC auto-inhibition, blocks the
increase in dopamine in nucleus accumbens that occurs when eating,
and acting synergistically with bupropion in augmenting POMC firing.
The COR-I and COR-II trials compared Contrave to diet and exercise
in patients who did not have DM.
The COR-Diabetes trial included the
same study design but focused on patients with DM. In all the studies the
participants had a 4-week titration
to Contrave (naltrexone 8 mg/bupropion 90 mg) to decrease nausea.
The first week dosing was 1 tablet in
the morning. Week 2 was 1 tablet in
morning and 1 tablet in the evening.
In week 3, patients took 2 tablets in
the morning and 1 tablet in the evening. The final titration step was
2 tablets in the morning and 2 tablets
in the evening.
The COR-1 study was a 56-week
randomized, double-blind, placebocontrolled study. It compared Contrave 32 mg naltrexone/360 mg
bupropion (NB32/360) with an active
placebo of diet and exercise.36 To be
included adults must be aged 18 to
65 years with a BMI 30 kg/m2 to 45
kg/m2 or a BMI 27 kg/m2 to 45 kg/m2
with dyslipidemia or hypertension.
Patients were instructed on a hypocaloric diet that was a 500 kcal per
day deficit based on World Health Organization algorithm for calculating
metabolic rate and they were urged to

increase physical activity.
The completer population results showed 8.0% weight loss in
the NB32/360 group and 1.9%
weight loss in the placebo group
(P < .001). For the NB32/360 and placebo groups, weight loss of ≥ 5% was
achieved by 48% and 16% (P <.001),
respectively; and weight loss of ≥ 10%
by 25% and 7% (P < .001), respectively. The most common AE was
nausea—29.8% with NB32/360 vs
5.3% with placebo. Nausea generally
occurred early and then diminished
and the discontinuation rate from
nausea was significantly lower (6.3%)
then the overall reported nausea rates.
Contrave was also studied in patients with T2DM. The COR-Diabetes Trial was a 56-week randomized,
double blind, placebo-controlled
study. The trial compared Contrave
32 mg naltrexone/360 mg bupropion
(NB32/360) with an active placebo of
diet and exercise.37 Inclusion criteria
for the trial were patients aged 18 to
70 years with T2DM and a BMI from
27 kg/m2 to 45 kg/m2, A1c between
7% and 10%, and fasting blood glucose < 270 mg/dL. Participants either
were not taking a DM medication or
were on stable doses of oral antidiabetes drugs ≥ 3 months prior to randomization. Patients were placed on
a 500 kcal hypocaloric diet and advised to increase physical activity.
The results showed 5.0% weight
loss in the NB32/360 group and 1.8%
weight loss in the placebo group
(P < .001). Weight loss of ≥ 5% and
≥ 10% was achieved by 44.5% and
18.5% of the NB32/360 group, respectively, and 18.9% and 5.7%, respectively (P < .001) of the placebo
group. The NB32/360 and placebo
showed a reduction of A1c of 0.6%
and 0.1% respectively (P < .001).
The most common AE was nausea
(42.3% with NB32/360 vs 7.1% with
placebo). Nausea generally occurred
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early and then diminished and the
discontinuation rate from nausea was
significantly lower (9.6%) then the
overall reported nausea rates.37
Due to potential nausea caused by
naltrexone, Contrave should be titrated over 4 weeks as described earlier. At maintenance dose, patients
should be evaluated after 12 weeks to
determine treatment benefits. If a patient has not lost at least 5% of baseline body weight, Contrave should
be discontinued, because it would be
unlikely that the patient will achieve
and sustain clinically meaningful
weight loss with continued treatment. Contrave should not be taken
with high-fat meals that may result in
significant increase in bupropion and
naltrexone systemic exposure.
Since Contrave contains the antidepressant bupropion, it has a boxed
warning similar to other antidepressants in its class of increased risk
of suicidal thoughts and behaviors,
especially in children, adolescents,
and young adults.38 Contrave can
lower the seizure threshold; therefore it should not be used in people
with a seizure disorder. It can also
raise BP and heart rate; however the
clinical significance of hypertension
and elevated heart rate observed with
Contrave treatment is unclear. Blood
pressure rose on average by 1 point
during the first 8 weeks of treatment
and then returned to baseline.38 The
heart rate also increased by about
1.7 beats per minute.38 Patients with
uncontrolled hypertension should
avoid Contrave.
Contrave should not be taken
with products contain bupropion or
naltrexone. It should not be taken
by patient who are regularly taking
opioids or who are opioid dependent, or who are experiencing opiate
withdrawal. Pregnant women should
also avoid Contrave. In patients with
renal impairment the maximum dose
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is 1 tablet twice a day and in patients
with hepatic impairment the maximum dose is 1 tablet a day.

LIRAGLUTIDE
Liraglutide is the newest weight loss
medication to be approved by the
FDA for chronic weight management
as an adjunct to a reduced calorie
diet and increased physical activity
in adult patients with BMI ≥ 30 kg/
m2 or ≥ 27 kg/m2 with hypertension,
diabetes, or dyslipidemia. The recommended dose of liraglutide is 3 mg
daily. The initial dose is 0.6 mg daily
for the first week, then titrated up
by 0.6 each week for 4 weeks, until
reaching 3 mg daily.
Liraglutide is an acylated human
glucagon-like peptide-1 (GLP-1) receptor agonist, which are expressed
in the brain and is involved in the
control of appetite. It is also found
in the beta cells of the pancreas,
where GLP-1 receptors stimulate insulin release in response to elevated
blood glucose concentrations and
suppress glucagon secretion. Endogenous GLP-1 has a half-life of 1.5 to
2 minutes due to degradation by the
DDP-4 enzyme, but liraglutide is stable against degradation by peptidases
and has a half- life of 13 hours.
Liraglutide was studied in a
56-week randomized, double-blind,
placebo-controlled trial, which compared liraglutide 3 mg with an active
placebo of diet and physical activity.39
Inclusion criteria were adults aged
≥ 18 years old with a BMI 30 kg/
m2 to 45 kg/m2 or BMI 27 kg/m2 to
45 kg/m2 with dyslipidemia and/or
hypertension. Both groups received
lifestyle modification counseling. Patients were excluded if they had DM.
In the trial, 3,731 participants
enrolled, 2,487 in the liraglutide
group and 1,244 in the placebo
group; 78.7% of the participants
were female and the average age
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was 45 years. Subjects in the liraglutide group had a weekly titration
regimen. The starting dose at week
1 was 0.6 mg, week 2 was 1.2 mg,
week 3 was 1.8 mg, week 4 was
2.4 mg, and week 5 was 3.0 kg.
The completer population
showed 9.2% weight loss in the liraglutide group and 3.0% weight loss
in the control group.39 Weight loss of
≥ 5% was seen in 63.2% and 27.1%
of the liraglutide and placebo groups,
respectively. Weight loss rates of
≥ 10% was seen by 33.1% and
10.6%, respectively. The most common AEs were nausea, diarrhea, and
constipation. Nausea generally occurred early during the titration period and then diminished.
A second clinically relevant study
was performed with liraglutide. Often
patients are able to lose weight with
diet and exercise and then plateau.
This study examined participants
who lost 5% percent of their initial
body weight and then were randomized to liraglutide or placebo.40 Key
inclusion criteria were people aged
≥ 18 years old with a BMI 30 kg/m2
to 45 kg/m2 or BMI 27 kg/m2 to 45
kg/m2 with dyslipidemia and/or hypertension. In order to be randomized, participants were required to
lose at least 5% of their initial body
weight on a 1,200 kcal to 1,400 kcal
diet with increased physical activity
during a 4 to 12 week run-in period.
Four hundred twenty-two participants were enrolled, 212 in the liraglutide group and 210 in the placebo
group. Most of the participants were
female (81%). The average BMI in
the study was 35.6 kg/m2. Subjects
in the liraglutide group had a weekly
titration regimen.
After an average weight loss of 6%
using a low calorie diet and increased
physical activity the participants were
randomized to continue diet and
increased activity alone (placebo)
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or with liraglutide. At week 56 the
results showed an additional 6.2%
weight loss in the liraglutide group
and 0.2% weight gain in the placebo
group. The liraglutide group had a
greater number of participants with
≥ 5% weight loss compared to placebo, 50.5% vs 21.8% (P < .0001).40
In the pooled data set from the registration trials the 3 most common GI
AEs were nausea, diarrhea, and constipation occurring in 39.3%, 20.9%,
and 19.4% of participants respectively. Discontinuation due to nausea
for liraglutide was 2.9%.41
Clinicians should be aware that
medications that can cause hypoglycemia such as sulfonylureas and
insulin must be tapered as patients
lose weight with liraglutide. Documented symptomatic hypoglycemia
in patients with T2DM and with sulfonylurea background therapy was
43.6% with liraglutide vs 27.3% with
placebo.
In the setting of renal impairment,
patients treated with GLP-1 receptor
agonists, including liraglutide, have
had reports of acute renal failure and
worsening of chronic renal failure
usually associated with nausea, vomiting, diarrhea, or dehydration. Liraglutide causes thyroid C-cell tumors
at clinically relevant exposures in rats
and mice. It is unknown whether
liraglutide causes thyroid C-cell tumors, including medullary thyroid
carcinoma (MTC), in humans. As
the human relevance of liraglutideinduced rodent thyroid C-cell tumors
has not been determined liraglutide
is contraindicated in patients with a
personal or family history of MTC or
in patients with multiple endocrine
neoplasia syndrome type 2.
Acute pancreatitis, including fatal
and nonfatal hemorrhagic or necrotizing pancreatitis, has been observed
in patients treated with liraglutide
in postmarketing reports. After ini-
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tiation of liraglutide, observe patients
carefully for signs and symptoms of
pancreatitis (including persistent severe abdominal pain, sometimes radiating to the back, which may or may
not be accompanied by vomiting). If
pancreatitis is suspected, liraglutide
should promptly be discontinued.

CONCLUSION
The treatment of obesity and overweight with comorbidities has always
been a challenge. In the past there
were few FDA-approved drugs and
many drugs had to be used off-label.
The toolbox of medications available for medical weight management is more robust than ever. The
medications have different MOAs
and can be used in a variety of patients. There are differences in the
classes and some are controlled substances. Phentermine, lorcaserin, and
Qsymia (phentermine/topiramate)
are controlled substances whereas
orlistat, naltrexone/bupropion and
liraglutide are not. Other differences
exist including duration of use. The
sympathomimetic drugs have a limited window of use whereas orlistat,
Qsymia (phentermine/topiramate),
lorcaserin, naltrexone/bupropion,
and liraglutide do not.
The medications that are available
have a wide variety of MOAs. Therefore, if a patient fails one medication, then it is very reasonable to try
a medication with a different MOA.
In addition, there is the potential for
weight regain when weight reduction medications are discontinued.
As people lose weight their metabolic rate decreases about 15 kcal per
pound of weight reduction.42
Another challenge of using these
medications is managing patient expectations. The current metric used
for FDA approval is a 5% weight loss
that is greater in the study group
compared with the diet and physi-

cal activity active control. However,
many clinicians and patients do not
find this weight reduction amount
consistent with their expectations.
In addition weight loss trajectory
may also be too slow for patients
and cause early discontinuation.
Therefore, patient education and a
discussion of reasonable expectations for weight reduction medications are necessary.
Clinicians must acknowledge
that there are limitations to the use
of these medications. Newer agents
do have a higher cost and insurance reimbursement is somewhat
limited. However, they offer the opportunity to prevent more expensive, protracted conditions such as
diabetes and cardiovascular disease.
In summary, clinicians now have a
wider variety of medication options
to be used with dietary and lifestyle
changes in order to improve health
and prevent chronic diseases. l
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adverse effects—before administering
pharmacologic therapy to patients.

11.
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